{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "d1469565b9e77ff7fd145848184cb67d",
    "title": "Jefferies",
    "source_uri": "2025-08-31/Soft 2Q25 as Expected 3Q25 Recovery GuidedSoft 2Q25 as Expected 3Q25 Recovery Guided_2025-08-31",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-27T00:44:46.148387",
      "extracted_at": "2025-10-27T00:44:46.148396"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 9,
        "successful_pages": 9,
        "date": "2025-08-31",
        "publication": "2025-08-31",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 2,
          "removed_paragraphs": 5,
          "reduction_ratio": 0.31787660300511866
        },
        "input_relative_path": "2025-08-31"
      }
    }
  },
  "passages": [
    {
      "passage_id": "349bee2712cbbe36",
      "text": "China (PRC) | Medical Supplies & Devices Mindray",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "7c7c49e3c6aa2da6",
      "text": "Weak 1H25 as expected with rev at Rmb16.7bn (- 18% yoy), and profit at Rmb5.1bn (- 33% yoy), dragged mainly by IVD biz. Mgmt expects 3Q25 rev growth to swing back to positive on accelerating overseas biz (EM at \\(15\\% +\\) yoy) and recovery of China biz. CN hospital procurement data already shows good sign of recovery in 1H25, w/ est. 6- 9 month delay from contribution to revenue. In short term, challenges remain from IVD VBP and DRG/DIP. Maintain Buy with PT at Rmb300.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "8b3494bd723b1b99",
      "text": "1H25 result - Mindray's reported 1H25 revenue at Rmb16.7bn (- 18% yoy), and net profit at Rmb5.1bn (- 33% yoy). Overseas sales grew 5% yoy, with rev contribution at 49.8%; China sales down 33.4% yoy. GM was down to 61.7% (vs 66.3% in 1H24) on IVD price cut after VBP. Selling expense ratio was stable at 14.5% (vs 14.3% in 1H24). R&D expense ratio increased to 9.6% (vs 8.6% in 1H24). Mgmt expects 3Q25 rev growth to swing back to positive on accelerating overseas growth (EM at \\(15\\% +\\) yoy in 2H25/2026E) and recovery of China business.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "e7315c3fac4207cb",
      "text": "1. IVD - 1H25 IVD revenue was Rmb6.5mn (-16% yoy). Overseas business grew by 12% and accounted for 37% of total IVD sales. Mgmt noted the company has 12.8% share in the China IVD mkt and expects this to reach 20% within 3 years, leveraging its leading position in new equipment installment (34.2% mkt shr YTD). In addition, the company targets to install 200 units for TLA (total laboratory automation) workflow in 2025 (completed \\(\\sim 100\\) units in 1H25).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "dc671230d3782bbe",
      "text": "2. MIS - 1H25 sales were Rmb3.3bn (-23% yoy). Overseas MIS sales grew 6% and contributed 62% of MIS revenue. High-end ultrasound booked Rmb400mn sales and is targetted to reach Rmb800mn in 2025.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "8654a741f09b9a5e",
      "text": "3. PMLS - 1H25 sales were Rmb5.5bn (-31% yoy). Overseas sales accounted for 67% of total PMLS revenue.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d7f3493853be5ace",
      "text": "Mgmt guides 3Q25 infection despite continued challenges in China - Mgmt expects 3Q25 rev growth to return to positive on accelerating overseas growth (EM at \\(15\\% +\\) yoy) and recovery of China business. We think challenges remain for the China business, particularly IVD, given 1) 1st round VBP on CLIA IVD reagents (anti-infectious) implemented in 3Q24, while 2nd round VBP (oncology) will be implemented soon; and 2) overall IVD mkt size to shrinks on unnecessary test cuts (such as test unbundling) required by DRG/DIP. Mgmt expects 1) higher penetration of CLIA 3 hospitals (current at 40%); and 2) to achieve 50% cost savings in 3 years to ease DRG/DIP pressure on IVD products.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "9728415eca254d55",
      "text": "Hospitai procurement data showing signs of recovery - 1H25 hospital procurement data is 64% yoy with 52% yoy in PMLS and 93% yoy medical imaging segment. We est. a 6- 9 month delay from hospital procurement to revenue contribution, supportive of company guidance of 3Q inflection. See details: link.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "f243375c5fcc87f3",
      "text": "Implications - We adjust our rev. estimate downwards to reflect slower recovery and weak IVD business. Over the long term, we like Mindray as a quality equipment leader with proven overseas track record, despite VBP challenges in the short term. Maintain Buy with PT at Rmb300.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "e941d5a60cdd8a50",
      "text": "2023A2024A2025E2026EEPS9.569.638.469.46Rev. (MM)34,931.936,725.834,917.840,698.2Net Profit11,582.211,668.510,242.311,463.2FY P/E25.4x25.2x28.7x25.7x",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "316e385bb02ed62c",
      "text": "Please see analyst certifications, important disclosure information, and information regarding the status of non-US analysts on pages 4-9 of this report. \\\\* Jefferies Hong Kong Limited",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "b1f89b597ae12c98",
      "text": "RATINGBUYPRICERmb242.79*PRICE TARGET | % TO PTRmb300.00 | +24%52W HIGH-LOWRmb351.60 - Rmb206.80FLOAT (%) | ADV MM (USD)100.1% | 2,112.28MARKET CAPRMB294.1B | $41.2BTICKER300760 CH",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "96b0fc2b4596b70c",
      "text": "\\\\*Prior trading day's closing price unless otherwise noted. Price: As of 17 Oct 2024",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "f7eb2a29febc292e",
      "text": "FY (Dec)CHANGE TO JEFEJEF vs CONS2025202620252026REV-11%-7%NANAEPS-15%-11%NANA",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "7a4709b779190bc9",
      "text": "2025 (RMB)Q1Q2Q3Q4FYEPS----Â±8.46PREV9.89",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "180884c035d9d62f",
      "text": "We rate Mindray a Buy for: 1) its global footprint expansion, supported by established sales network and brand recognition, 2) its diversified portfolio, positioned for growth amid medical equipment renewal policies, with in- house R&D focused on the high- end ultrasound market, 3) industry integration to strengthen core business and unlock new growth drivers.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "f6c6d3e3fa19cf3d",
      "text": "Risk/Reward - 12 Month View",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "1bb3fa767d4fc493",
      "text": "Base Case, CNY300, +24%",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "a9bc0b8ece5d9baa",
      "text": "Revenue growth of 7%/11%/12% YoY in 2025E/26E/27E.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "1e683b7ffcca1402",
      "text": "Our PT of Rmb300 is DCF- based.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "b58f26392c15db64",
      "text": "Upside Scenario, CNY350, +44%",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "250ee10a7b6e42e6",
      "text": "Revenue growth of 15%/20%/20% YoY in 2025E/26E/27E.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "5d3c581de787ee0f",
      "text": "Our upside PT of Rmb350 is DCF- based.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "6e93a4bf454a28a0",
      "text": "Downside Scenario, CNY180, - 26%",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "d15ce2cbf56ee2bc",
      "text": "Revenue growth of 3%/5%/7% YoY in 2025E/26E/27E.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "05673546668faba8",
      "text": "Our downside PT of Rmb180 is DCF- based.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "4b0077dc9011101c",
      "text": "Top Material Issues:",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "7c81d8544e86af07",
      "text": "1) Corporate governance, 2) insightful innovation, 3) value chain collaboration, 4) green development, 5) sustainable human resources, 6) social responsibility.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "8db0b1753d4841a9",
      "text": "Greenhouse gas emission: achieve - 25% reduction in carbon emission by 2030 compared with that in 2021.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "d1588397752a7897",
      "text": "Questions to management:",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "7cc008569627fd5e",
      "text": "1) What are the projected investments and potential savings in achieving the established ESG targets?",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "e15fe9ed03ff64e7",
      "text": "2) How will compliance with ESG standards affect profit margin?",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "22fbf9080cfb0e98",
      "text": "+ Faster- than- expected medical equipment renewal cycle to benefit ultrasound and ICU businesses - 2025- Potential GPO on ultrasound equipment - 2025- Margin pressure on IVD from GPO - 2025",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "c49fbcba6bbe0ed9",
      "text": "Source: Company data, Jefferies estimates",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "028450147fbd046a",
      "text": "MindrayMindray is a domestic leading medical- device manufacturer and solution provider. The company operates in three major product lines covering PMLS, IVD and Medical Imaging, each accounting for \\(37\\%\\) , \\(37\\%\\) , \\(20\\%\\) of its 2024 revenue.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "fb3180c5520337de",
      "text": "Our price target of Rmb300.0 is based on DCF, which factors in our revenue and earnings forecasts up to 2034E, with WACC of \\(8.8\\%\\) and terminal growth rate at \\(3.0\\%\\) .",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "07604aa62891346c",
      "text": "Geopolitical risk - \\(45\\%\\) of Mindray's revenue came from overseas markets in 2024. Geopolitical risks such as the U.S.- China trade tension may affect Mindray's revenue, investment, or raw materials sourcing.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "49eb35a66bfc33ae",
      "text": "GPO risk - IVD products have been involved in multiple batches of GPOs at both provincial and city level. Mindray faces price cut risks from the campaigns which may lead to lower- than- expected sales in this sector.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "c6d151f679f42e67",
      "text": "Patent risk - Mindray has patents issued in China and the US, covering various products. If Mindray is unable to obtain patent protection for certain aspects of the products or technologies due to varying regulation requirements, the company's business and competitive position would be adversely affected.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "c8ea2bfc53124fc5",
      "text": "(Article 3(1)e and Article 7 of MAR) Recommendation Published",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "ff9f4877e6117f0c",
      "text": "August 31, 2025 8:47 A.M.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "35bc628c167191d3",
      "text": "Buy - Describes securities that we expect to provide a total return (price appreciation plus yield) of \\(15\\%\\) or more within a 12- month period. Hold - Describes securities that we expect to provide a total return (price appreciation plus yield) of plus \\(15\\%\\) or minus \\(10\\%\\) within a 12- month period. Underperform - Describes securities that we expect to provide a total return (price appreciation plus yield) of minus \\(10\\%\\) or less within a 12- month period. The expected total return (price appreciation plus yield) for Buy rated securities with an average security price consistently below \\(10\\) is \\(20\\%\\) or more within a 12- month period as these companies are typically more volatile than the overall stock market. For Hold rated securities with an average security price consistently below \\(10\\) , the expected total return (price appreciation plus yield) is plus or minus \\(20\\%\\) within a 12- month period. For Underperform rated securities with an average security price consistently below \\(10\\) , the expected total return (price appreciation plus yield) is minus \\(20\\%\\) or less within a 12- month period.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "7dff5834781cc292",
      "text": "NR - The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Jefferies policies.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "2cdad0cdc02370fa",
      "text": "CS - Coverage Suspended. Jefferies has suspended coverage of this company.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "63fd3083da3e7581",
      "text": "NC - Not covered. Jefferies does not cover this company.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "596ffb1a3561c9af",
      "text": "Restricted - Describes issuers where, in conjunction with Jefferies engagement in certain transactions, company policy or applicable securities regulations prohibit certain types of communications, including investment recommendations.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "c876a9abffb92ce9",
      "text": "Monitor - Describes securities whose company fundamentals and financials are being monitored, and for which no financial projections or opinions on the investment merits of the company are provided.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "79e1daef8aba9902",
      "text": "Jefferies methodology for assigning ratings may include the following: market capitalization, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "1f5c98100ac8f326",
      "text": "Jefferies Franchise Picks include stock selections from among the best stock ideas from our equity analysts over a 12 month period. Stock selection is based on fundamental analysis and may take into account other factors such as analyst conviction, differentiated analysis, a favorable risk/reward ratio and investment themes that Jefferies analysts are recommending. Jefferies Franchise Picks will include only Buy rated stocks and the number can vary depending on analyst recommendations for inclusion. Stocks will be added as new opportunities arise and removed when the reason for inclusion changes, the stock has met its desired return, if it is no longer rated Buy and/or if it triggers a stop loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a \\(15\\%\\) stop loss, and the remainder will have a \\(20\\%\\) stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not sector based, but we may note where we believe a Pick falls within an investment style such as growth or value.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "ffe41a325a7494f5",
      "text": "Rating and Price Target History for: Mindray (300760 CH) as of 08-29-2025",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "6f17139f8ba55299",
      "text": "Notes: Each box in the Rating and Price Target History chart above represents actions over the past three years in which an analyst initiated on a company, made a change to a rating or price target of a company or discontinued coverage of a company. Legend:",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "dc905642821902b2",
      "text": "I: Initiating Coverage \nD: Dropped Coverage \nB: Buy \nH: Hold \nUP: Underperform",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "522bc7f01fc00716",
      "text": "Distribution of Ratings",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "0ee2f3d7f759dbb7",
      "text": "CountPercentCountPercentCountPercentBUY210760.60%37017.56%1185.60%HOLD121234.86%1078.83%221.82%UNDERPERFORM1584.54%31.90%31.90%",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "230c4a6f8de5f28c",
      "text": "Jefries does busines and seeks to do busines with companies covered in its research reports, and expects to receive or intends to seek compensation for investment banking services among other activities from such companies. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Jefferies Equity Research refers to research reports produced by analysts employed by one of the following Jefferies Financial Group Inc. (Jefferies) companies:",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "e921ebe37be2728e",
      "text": "United States: Jefferies LLC which is an SEC registered broker- dealer and a member of FINRA (and distributed by Jefferies Research Services, LLC, an SEC registered Investment Adviser, to clients paying separately for such research).",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "cbca081d97debfb1",
      "text": "Canada: Jefferies Securities Inc., which is an investment dealer registered in each of the thirteen Canadian jurisdictions and a dealer member of the Canadian Investment Regulatory Organization, including research reports produced jointly by Jefferies Securities Inc. and another Jefferies entity (and distributed by Jefferies Securities Inc.).",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "5fda41e5b2f73933",
      "text": "Where Jefferies Securities Inc. distributes research reports produced by Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch or Jefferies India Private Limited, you are advised that each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited operates as a dealer in your jurisdiction under an exemption from the dealer registration requirements contained in National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations and, as such, each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited is not required to be and is not a registered dealer or adviser in your jurisdiction. You are advised that where Jefferies LLC or Jefferies International Limited prepared this research report, it was not prepared in accordance with Canadian disclosure requirements relating to research reports in Canada.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "3fe39309fb957cab",
      "text": "United Kingdom: Jefferies International Limited, which is authorized and regulated by the Financial Conduct Authority, registered in England and Wales No. 1978621; registered office: 100 Bishopsgate, London EC2N 4JL; telephone +44 (0)20 7029 8000; facsimile +44 (0)20 7029 8010.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "b4a3ae84c10509f8",
      "text": "Japan: Jefferies (Japan) Limited, Tokyo Branch, which is a securities company registered by the Financial Services Agency of Japan and is a member of the Japan Securities Dealers Association; located at Tokyo Midtown Hibiya 30F Hibiya Mitsui Tower, 1- 1- 2 Yurakucho, Chiyoda- ku, Tokyo 100- 0006; telephone +813 5251 6100; facsimile +813 5251 6101.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "839c3aca1e3dc1e6",
      "text": "Australia: Jefferies (Australia) Pty Limited (ACN 623 059 898), which holds an Australian financial services license (AFSL 504712) and is located at Level 20, 60 Martin Place, Sydney NSW 2000; telephone +61 2 9364 2800.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "1124a431053d9548",
      "text": "Dubai: Jefferies International Limited, Dubai branch, which is licensed by the Dubai Financial Services Authority (DFSA Reference Number F007325); registered office Unit L31- 06, L31- 07, Level 31, ICD Brookfield Pace, DIFC, PO Box 121208, Dubai, UAE.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "321dd51deb5bbd56",
      "text": "This report was prepared by personnel who are associated with Jefferies (Jefferies Securities Inc., Jefferies International Limited, Jefferies GmbH, Jefferies Hong Kong Limited, Jefferies Singapore Limited, Jefferies (Japan) Limited, Tokyo Branch, Jefferies India Private Limited), and Jefferies (Australia) Pty Ltd; or by personnel who are associated with both Jefferies LLC and Jefferies Research Services LLC (\"JRS\"). Jefferies LLC is a US registered broker- dealer and is affiliated with JRS, which is a US registered investment adviser. JRS does not create tailored or personalized research and all research provided by JRS is impersonal. If you are paying separately for this research, it is being provided to you by JRS. Otherwise, it is being provided by Jefferies LLC. Jefferies LLC, JRS, and their affiliates are collectively referred to below as \"Jefferies\". Jefferies may seek to do business with companies covered in this research report. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only one of many factors in making their investment decisions. Specific conflict of interest and other disclosures that are required by FINRA, the Canadian Investment Regulatory Organization and other rules are set forth in this disclosure section.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "107189319e3c7bb2",
      "text": "If you are receiving this report from a non- US Jefferies entity, please note the following: Unless prohibited by the provisions of Regulation S of the U.S. Securities Act of 1933, as amended, this material is distributed in the United States by Jefferies LLC, which accepts responsibility for its contents in accordance with the provisions of Rule 15a- 6 under the US Securities Exchange Act of 1934, as amended. Transactions by or on behalf of any US person may only be effected through Jefferies LLC. In the United Kingdom and European Economic Area this report is issued and/or approved for distribution by Jefferies International Limited (\"JIL\") and/or Jefferies GmbH and is intended for use only by persons who have, or have been assessed as having, suitable professional experience and expertise, or by persons to whom it can be otherwise lawfully distributed. Jefferies LLC, JIL, Jefferies GmbH and their affiliates, may make a market or provide liquidity in the financial instruments referred to in this report; and where they do make a market, such activity is disclosed specifically in this report under \"company specific disclosures\".",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "d6c3f97d3dcf667f",
      "text": "For Canadian investors, this material is intended for use only by professional or institutional investors. None of the investments or investment services mentioned or described herein is available to other persons or to anyone in Canada who is not a \"permitted client\" as defined by National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations, as applicable. This research report is a general discussion of the merits and",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "6502e6c976152c1d",
      "text": "first considering whether any advice or recommendation in this report is suitable for the recipient based on the recipient's particular circumstances and, if appropriate or otherwise needed, seeking professional advice, including tax advice. Jefferies does not perform any suitability or other analysis to check whether an investment decision made by the recipient based on this report is consistent with a recipient's investment objectives, portfolio holdings, strategy, financial situation, or needs.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "d57f1b53836a36bb",
      "text": "By providing this report, neither JRS nor any other Jefferies entity accepts any authority, discretion, or control over the management of the recipient's assets. Any action taken by the recipient of this report, based on the information in the report, is at the recipient's sole judgment and risk. The recipient must perform his or her own independent review of any prospective investment. If the recipient uses the services of Jefferies LLC (or other affiliated broker- dealers), in connection with a purchase or sale of a security that is a subject of these materials, such broker- dealer may act as principal for its own accounts or as agent for another person. Only JRS is registered with the SEC as an investment adviser; and therefore neither Jefferies LLC nor any other Jefferies affiliate has any fiduciary duty in connection with distribution of these reports.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "2d79f37fd24f2b3c",
      "text": "The price and value of the investments referred to herein and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "8c560c1dac16a3b0",
      "text": "This report may contain forward looking statements that may be affected by inaccurate assumptions or by known or unknown risks, uncertainties, and other important factors. As a result, the actual results, events, performance or achievements of the financial product may be materially different from those expressed or implied in such statements.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "b201f20d64a0ad2c",
      "text": "This report has been prepared independently of any issuer of securities mentioned herein and not as agent of any issuer of securities. No Equity Research personnel have authority whatsoever to make any representations or warranty on behalf of the issuer(s). Any comments or statements made herein are those of the Jefferies entity producing this report and may differ from the views of other Jefferies entities.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "5bb3c833273a3c6a",
      "text": "This report may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor's, and information derived from third- party or proprietary generative artificial intelligence (Gen AI) models. Jefferies does not guarantee the accuracy, completeness, timeliness or availability of this information, and is not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Neither Jefferies nor any third- party content providers, including providers of Gen AI models, give any express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Neither Jefferies nor any third- party content provider shall be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs,",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "c23caf4943fcce2f",
      "text": "expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase, hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "2d04cc6fd884e620",
      "text": "Jefferies research reports are disseminated and available electronically, and, in some cases, also in printed form. Electronic research is simultaneously made available to all clients. This report or any portion hereof may not be copied, reprinted, sold, or redistributed or disclosed by the recipient or any third party, by content scraping or extraction, automated processing, or any other form or means, without the prior written consent of Jefferies. Any unauthorized use is prohibited. Neither Jefferies nor any of its respective directors, officers or employees, is responsible for guaranteeing the financial success of any investment, or accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this report or its contents. Nothing herein shall be construed to waive any liability Jefferies has under applicable U.S. federal or state securities laws.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "082095b815c595af",
      "text": "For Important Disclosure information relating to JRS, please see https://adviserinfo.sec.gov/IAPD/Content/Common/crd_iapd_Brochure.aspx? BRCHR_VRSN_ID=483878 and https://adviserinfo.sec.gov/Firm/292142 or visit our website at https://javatar.bluematrix.com/sellside/Disclosures.action, or www.jefferies.com, or call 1.888. JEFFERIES.",
      "page": 8,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "091ea27f0512d847",
      "name": "Base Case",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7860a2554c61a53f",
      "name": "Canadian Investment",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "f5b8c080cdc5f7aa",
      "name": "Catalysts\n\nTop",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "5089a9eaa876e184",
      "name": "China IVD",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6e4788dbad025b7b",
      "name": "Company Description",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8bb7d9a681cb9e40",
      "name": "Company Valuation",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4b9be408e155a05b",
      "name": "Coverage Suspended",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e9cd18ef1469e32c",
      "name": "DFSA Reference",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6ba4b0a762d135f4",
      "name": "Dealers Association",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8dab40b09958541b",
      "name": "Devices Mindray",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ef7939250a8b4d95",
      "name": "Differ\n\nWe",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e736f0c0f1f7561e",
      "name": "Disclosures\n\nJefries",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "98c5e1b74a254ba0",
      "name": "Downside Scenario",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a87247c304f6889b",
      "name": "Dropped Coverage",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8ed3fafbb18d7293",
      "name": "Dubai Financial",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "21bc9aa97d2d9364",
      "name": "European Economic",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "88ae349d7f27936d",
      "name": "Exchange Act",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "c30d804de2e4ac53",
      "name": "Financial Conduct",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "f279b250fb9ccc9a",
      "name": "Financial Services",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "9acf1646d3aff849",
      "name": "For Canadian",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "line",
        "title": "Rating and Price Target History for: Mindray (300760 CH) as of 08-29-2025",
        "page": 6,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Oct 22",
              "Jan 23",
              "Apr 23",
              "Jul 23",
              "Oct 23",
              "Jan 24",
              "Apr 24",
              "Jul 24",
              "Oct 24",
              "Jan 25",
              "Apr 25",
              "Jul 25"
            ]
          },
          "y": {
            "unit": "CNY",
            "range": {
              "min": 200,
              "max": 360
            }
          }
        },
        "series": [
          {
            "name": "Price",
            "unit": "CNY",
            "values": [
              295,
              280,
              340,
              300,
              310,
              290,
              270,
              280,
              310,
              290,
              270,
              250,
              230,
              210,
              220,
              240,
              250
            ]
          },
          {
            "name": "Price Target 10/22/2024",
            "unit": "CNY",
            "values": [
              {
                "date": "10/22/2024",
                "value": 350
              }
            ]
          },
          {
            "name": "Price Target 04/30/2025",
            "unit": "CNY",
            "values": [
              {
                "date": "04/30/2025",
                "value": 300
              }
            ]
          }
        ],
        "figure_id": "af9f616c81888b7f",
        "provenance": {
          "page": 6
        }
      },
      {
        "type": "other",
        "title": null,
        "page": 1,
        "axes": null,
        "series": [],
        "figure_id": "51c07a8cf56a0363",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "other",
        "title": null,
        "page": 2,
        "axes": {
          "x": {
            "type": "other",
            "labels": []
          },
          "y": {
            "unit": null,
            "range": {
              "min": null,
              "max": null
            }
          }
        },
        "series": [],
        "figure_id": "e0628892fa41155d",
        "provenance": {
          "page": 2
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "a462c110627b194f",
        "value": 0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "pg) ## Soft 2Q25 as Expected; 3Q25 Recovery Guided Weak 1H25 as expected with rev at Rmb16.7bn (- 18% yoy), and profit at Rmb5.1bn (- 33% yoy), dragged mainly by IVD biz. Mgmt expects 3Q25 rev growth ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "f0a840a314d4b805",
        "value": 0.33,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Recovery Guided Weak 1H25 as expected with rev at Rmb16.7bn (- 18% yoy), and profit at Rmb5.1bn (- 33% yoy), dragged mainly by IVD biz. Mgmt expects 3Q25 rev growth to swing back to positive on accele",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "249c050e8ee3f1ec",
        "value": 0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "DIP. Maintain Buy with PT at Rmb300. 1H25 result - Mindray's reported 1H25 revenue at Rmb16.7bn (- 18% yoy), and net profit at Rmb5.1bn (- 33% yoy). Overseas sales grew 5% yoy, with rev contribution a",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "ac07958ca7933163",
        "value": 0.33,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "25 result - Mindray's reported 1H25 revenue at Rmb16.7bn (- 18% yoy), and net profit at Rmb5.1bn (- 33% yoy). Overseas sales grew 5% yoy, with rev contribution at 49.8%; China sales down 33.4% yoy. GM",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "1350e41359b671e6",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1H25 revenue at Rmb16.7bn (- 18% yoy), and net profit at Rmb5.1bn (- 33% yoy). Overseas sales grew 5% yoy, with rev contribution at 49.8%; China sales down 33.4% yoy. GM was down to 61.7% (vs 66.3% in",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "01377a35cee11b16",
        "value": 0.498,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "yoy), and net profit at Rmb5.1bn (- 33% yoy). Overseas sales grew 5% yoy, with rev contribution at 49.8%; China sales down 33.4% yoy. GM was down to 61.7% (vs 66.3% in 1H24) on IVD price cut after VBP",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "2174b866397a7832",
        "value": 0.33399999999999996,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Rmb5.1bn (- 33% yoy). Overseas sales grew 5% yoy, with rev contribution at 49.8%; China sales down 33.4% yoy. GM was down to 61.7% (vs 66.3% in 1H24) on IVD price cut after VBP. Selling expense ratio ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "62d78d46ff9ff769",
        "value": 0.617,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "rseas sales grew 5% yoy, with rev contribution at 49.8%; China sales down 33.4% yoy. GM was down to 61.7% (vs 66.3% in 1H24) on IVD price cut after VBP. Selling expense ratio was stable at 14.5% (vs 1",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "909a4a5534f09d45",
        "value": 0.6629999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "s grew 5% yoy, with rev contribution at 49.8%; China sales down 33.4% yoy. GM was down to 61.7% (vs 66.3% in 1H24) on IVD price cut after VBP. Selling expense ratio was stable at 14.5% (vs 14.3% in 1H",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "47d3e8072362f668",
        "value": 0.145,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "as down to 61.7% (vs 66.3% in 1H24) on IVD price cut after VBP. Selling expense ratio was stable at 14.5% (vs 14.3% in 1H24). R&D expense ratio increased to 9.6% (vs 8.6% in 1H24). Mgmt expects 3Q25 r",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "1b03efb784e1b3cf",
        "value": 0.14300000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "61.7% (vs 66.3% in 1H24) on IVD price cut after VBP. Selling expense ratio was stable at 14.5% (vs 14.3% in 1H24). R&D expense ratio increased to 9.6% (vs 8.6% in 1H24). Mgmt expects 3Q25 rev growth t",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "19969319e8ff064d",
        "value": 0.096,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r VBP. Selling expense ratio was stable at 14.5% (vs 14.3% in 1H24). R&D expense ratio increased to 9.6% (vs 8.6% in 1H24). Mgmt expects 3Q25 rev growth to swing back to positive on accelerating overs",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "5f1b05a4243f484a",
        "value": 0.086,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "lling expense ratio was stable at 14.5% (vs 14.3% in 1H24). R&D expense ratio increased to 9.6% (vs 8.6% in 1H24). Mgmt expects 3Q25 rev growth to swing back to positive on accelerating overseas growt",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "f298959315c7c2c5",
        "value": -0.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "5\\% +\\) yoy in 2H25/2026E) and recovery of China business. 1. IVD - 1H25 IVD revenue was Rmb6.5mn (-16% yoy). Overseas business grew by 12% and accounted for 37% of total IVD sales. Mgmt noted the com",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "13dda0e31e203bf0",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ry of China business. 1. IVD - 1H25 IVD revenue was Rmb6.5mn (-16% yoy). Overseas business grew by 12% and accounted for 37% of total IVD sales. Mgmt noted the company has 12.8% share in the China IVD",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "b4e1322b93a51b7f",
        "value": 0.37,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1. IVD - 1H25 IVD revenue was Rmb6.5mn (-16% yoy). Overseas business grew by 12% and accounted for 37% of total IVD sales. Mgmt noted the company has 12.8% share in the China IVD mkt and expects this ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "477afa80206fb79c",
        "value": 0.128,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Overseas business grew by 12% and accounted for 37% of total IVD sales. Mgmt noted the company has 12.8% share in the China IVD mkt and expects this to reach 20% within 3 years, leveraging its leading",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "90e469b579c87e02",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "al IVD sales. Mgmt noted the company has 12.8% share in the China IVD mkt and expects this to reach 20% within 3 years, leveraging its leading position in new equipment installment (34.2% mkt shr YTD)",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "186a28f3c2bfe958",
        "value": 0.342,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "cts this to reach 20% within 3 years, leveraging its leading position in new equipment installment (34.2% mkt shr YTD). In addition, the company targets to install 200 units for TLA (total laboratory ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "c3b83f7ecb86d51d",
        "value": -0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ation) workflow in 2025 (completed \\(\\sim 100\\) units in 1H25). 2. MIS - 1H25 sales were Rmb3.3bn (-23% yoy). Overseas MIS sales grew 6% and contributed 62% of MIS revenue. High-end ultrasound booked ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "92c3fde8635a3260",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "\\(\\sim 100\\) units in 1H25). 2. MIS - 1H25 sales were Rmb3.3bn (-23% yoy). Overseas MIS sales grew 6% and contributed 62% of MIS revenue. High-end ultrasound booked Rmb400mn sales and is targetted to ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "5e8e21ec3d61f368",
        "value": 0.62,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "in 1H25). 2. MIS - 1H25 sales were Rmb3.3bn (-23% yoy). Overseas MIS sales grew 6% and contributed 62% of MIS revenue. High-end ultrasound booked Rmb400mn sales and is targetted to reach Rmb800mn in 2",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "d4e79389e0f78bf4",
        "value": -0.31,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ked Rmb400mn sales and is targetted to reach Rmb800mn in 2025. 3. PMLS - 1H25 sales were Rmb5.5bn (-31% yoy). Overseas sales accounted for 67% of total PMLS revenue. Mgmt guides 3Q25 infection despite",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "7020fe397b80c003",
        "value": 0.67,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "each Rmb800mn in 2025. 3. PMLS - 1H25 sales were Rmb5.5bn (-31% yoy). Overseas sales accounted for 67% of total PMLS revenue. Mgmt guides 3Q25 infection despite continued challenges in China - Mgmt ex",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "9d74ad42eb018135",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "unbundling) required by DRG/DIP. Mgmt expects 1) higher penetration of CLIA 3 hospitals (current at 40%); and 2) to achieve 50% cost savings in 3 years to ease DRG/DIP pressure on IVD products. Hospit",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "afc08427b7db63f5",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "DRG/DIP. Mgmt expects 1) higher penetration of CLIA 3 hospitals (current at 40%); and 2) to achieve 50% cost savings in 3 years to ease DRG/DIP pressure on IVD products. Hospitai procurement data show",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "ec20eb8c7f14678c",
        "value": 0.64,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "products. Hospitai procurement data showing signs of recovery - 1H25 hospital procurement data is 64% yoy with 52% yoy in PMLS and 93% yoy medical imaging segment. We est. a 6- 9 month delay from hosp",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "8a3e9967553bfa9a",
        "value": 0.52,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ospitai procurement data showing signs of recovery - 1H25 hospital procurement data is 64% yoy with 52% yoy in PMLS and 93% yoy medical imaging segment. We est. a 6- 9 month delay from hospital procur",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "f8501126bf3a66c0",
        "value": 0.93,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "data showing signs of recovery - 1H25 hospital procurement data is 64% yoy with 52% yoy in PMLS and 93% yoy medical imaging segment. We est. a 6- 9 month delay from hospital procurement to revenue con",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "0393d076a43bfc14",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "pan=\"2\">Rmb242.79*</td><td></td></tr><tr><td>PRICE TARGET | % TO PT</td><td colspan=\"2\">Rmb300.00 | +24%</td><td></td></tr><tr><td>52W HIGH-LOW</td><td colspan=\"2\">Rmb351.60 - Rmb206.80</td><td></td><",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "4b27f3e531b8a9e1",
        "value": 1.001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "an=\"2\">Rmb351.60 - Rmb206.80</td><td></td></tr><tr><td>FLOAT (%) | ADV MM (USD)</td><td colspan=\"2\">100.1% | 2,112.28</td><td></td></tr><tr><td>MARKET CAP</td><td colspan=\"2\">RMB294.1B | $41.2B</td><t",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "fde75b72506b44f4",
        "value": -0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "F vs CONS</td></tr><tr><td>2025</td><td>2026</td><td>2025</td><td>2026</td></tr><tr><td>REV</td><td>-11%</td><td>-7%</td><td>NA</td><td>NA</td></tr><tr><td>EPS</td><td>-15%</td><td>-11%</td><td>NA</td",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "62bb563cb748a46d",
        "value": -0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></tr><tr><td>2025</td><td>2026</td><td>2025</td><td>2026</td></tr><tr><td>REV</td><td>-11%</td><td>-7%</td><td>NA</td><td>NA</td></tr><tr><td>EPS</td><td>-15%</td><td>-11%</td><td>NA</td><td>NA</td><",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "bca6ba210b623704",
        "value": -0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "26</td></tr><tr><td>REV</td><td>-11%</td><td>-7%</td><td>NA</td><td>NA</td></tr><tr><td>EPS</td><td>-15%</td><td>-11%</td><td>NA</td><td>NA</td></tr></table> <table><tr><td>2025 (RMB)</td><td>Q1</td><",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "58c984f81b3205e2",
        "value": -0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><td>REV</td><td>-11%</td><td>-7%</td><td>NA</td><td>NA</td></tr><tr><td>EPS</td><td>-15%</td><td>-11%</td><td>NA</td><td>NA</td></tr></table> <table><tr><td>2025 (RMB)</td><td>Q1</td><td>Q2</td><td",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "a520ed5f6b7d442f",
        "value": 41200000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "colspan=\"2\">100.1% | 2,112.28</td><td></td></tr><tr><td>MARKET CAP</td><td colspan=\"2\">RMB294.1B | $41.2B</td><td></td></tr><tr><td>TICKER</td><td colspan=\"2\">300760 CH</td><td></td></tr></table> \\\\*P",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "761f0642b6ded600",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ". ![Figure 1-0](images/1_0.jpg) <center>Risk/Reward - 12 Month View </center> Base Case, CNY300, +24% Revenue growth of 7%/11%/12% YoY in 2025E/26E/27E. Our PT of Rmb300 is DCF- based. Upside Scenar",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "ca5adf05a928f3de",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1_0.jpg) <center>Risk/Reward - 12 Month View </center> Base Case, CNY300, +24% Revenue growth of 7%/11%/12% YoY in 2025E/26E/27E. Our PT of Rmb300 is DCF- based. Upside Scenario, CNY350, +44% Reve",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "bb2d17d98678919e",
        "value": 0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".jpg) <center>Risk/Reward - 12 Month View </center> Base Case, CNY300, +24% Revenue growth of 7%/11%/12% YoY in 2025E/26E/27E. Our PT of Rmb300 is DCF- based. Upside Scenario, CNY350, +44% Revenue",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "804f905dfa9f1d4c",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ") <center>Risk/Reward - 12 Month View </center> Base Case, CNY300, +24% Revenue growth of 7%/11%/12% YoY in 2025E/26E/27E. Our PT of Rmb300 is DCF- based. Upside Scenario, CNY350, +44% Revenue grow",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "81311a56ef824477",
        "value": 0.44,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "owth of 7%/11%/12% YoY in 2025E/26E/27E. Our PT of Rmb300 is DCF- based. Upside Scenario, CNY350, +44% Revenue growth of 15%/20%/20% YoY in 2025E/26E/27E. Our upside PT of Rmb350 is DCF- based. Downs",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "eb9fac123da6d3fb",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "n 2025E/26E/27E. Our PT of Rmb300 is DCF- based. Upside Scenario, CNY350, +44% Revenue growth of 15%/20%/20% YoY in 2025E/26E/27E. Our upside PT of Rmb350 is DCF- based. Downside Scenario, CNY180, -",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "67fac17217594c0e",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "25E/26E/27E. Our PT of Rmb300 is DCF- based. Upside Scenario, CNY350, +44% Revenue growth of 15%/20%/20% YoY in 2025E/26E/27E. Our upside PT of Rmb350 is DCF- based. Downside Scenario, CNY180, - 26%",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "706e137a398e73d9",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "26E/27E. Our PT of Rmb300 is DCF- based. Upside Scenario, CNY350, +44% Revenue growth of 15%/20%/20% YoY in 2025E/26E/27E. Our upside PT of Rmb350 is DCF- based. Downside Scenario, CNY180, - 26% Re",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "455e23d2fdcb12ae",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "20%/20% YoY in 2025E/26E/27E. Our upside PT of Rmb350 is DCF- based. Downside Scenario, CNY180, - 26% Revenue growth of 3%/5%/7% YoY in 2025E/26E/27E. Our downside PT of Rmb180 is DCF- based. ## Sus",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "12a80668d0902dbd",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "E/27E. Our upside PT of Rmb350 is DCF- based. Downside Scenario, CNY180, - 26% Revenue growth of 3%/5%/7% YoY in 2025E/26E/27E. Our downside PT of Rmb180 is DCF- based. ## Sustainability Matters #",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "b15005fe0a9f0911",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "7E. Our upside PT of Rmb350 is DCF- based. Downside Scenario, CNY180, - 26% Revenue growth of 3%/5%/7% YoY in 2025E/26E/27E. Our downside PT of Rmb180 is DCF- based. ## Sustainability Matters ## C",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "6f537a5c85d70ad9",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Our upside PT of Rmb350 is DCF- based. Downside Scenario, CNY180, - 26% Revenue growth of 3%/5%/7% YoY in 2025E/26E/27E. Our downside PT of Rmb180 is DCF- based. ## Sustainability Matters ## Cata",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "11cadae2f8bee30d",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "le human resources, 6) social responsibility. Company targets: Greenhouse gas emission: achieve - 25% reduction in carbon emission by 2030 compared with that in 2021. Questions to management: 1) What",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "388fb3e9ff2514e9",
        "value": 0.606,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>Count</td><td>Percent</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2107</td><td>60.60%</td><td>370</td><td>17.56%</td><td>118</td><td>5.60%</td><td></td></tr><tr><td>HOLD</td><td>1",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "037080e9905b5b84",
        "value": 0.17559999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2107</td><td>60.60%</td><td>370</td><td>17.56%</td><td>118</td><td>5.60%</td><td></td></tr><tr><td>HOLD</td><td>1212</td><td>34.86%</td><td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "e59f61ac8a24329f",
        "value": 0.055999999999999994,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ent</td></tr><tr><td>BUY</td><td>2107</td><td>60.60%</td><td>370</td><td>17.56%</td><td>118</td><td>5.60%</td><td></td></tr><tr><td>HOLD</td><td>1212</td><td>34.86%</td><td>107</td><td>8.83%</td><td>2",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "6d58f8b949ee3b69",
        "value": 0.3486,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>370</td><td>17.56%</td><td>118</td><td>5.60%</td><td></td></tr><tr><td>HOLD</td><td>1212</td><td>34.86%</td><td>107</td><td>8.83%</td><td>22</td><td>1.82%</td><td></td></tr><tr><td>UNDERPERFORM</td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "8aaef7087aea3a18",
        "value": 0.0883,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>118</td><td>5.60%</td><td></td></tr><tr><td>HOLD</td><td>1212</td><td>34.86%</td><td>107</td><td>8.83%</td><td>22</td><td>1.82%</td><td></td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "87f4f3bcb29ad4bb",
        "value": 0.0182,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td></td></tr><tr><td>HOLD</td><td>1212</td><td>34.86%</td><td>107</td><td>8.83%</td><td>22</td><td>1.82%</td><td></td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "685c5d188459e721",
        "value": 0.0454,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "7</td><td>8.83%</td><td>22</td><td>1.82%</td><td></td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td><td>1.90%</td><td></td></tr></table><ï½endâofâsentenceï½>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "1f2eb274184fdb6d",
        "value": 0.019,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "22</td><td>1.82%</td><td></td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td><td>1.90%</td><td></td></tr></table><ï½endâofâsentenceï½>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "71f57f639100208c",
        "value": 0.019,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td><td>1.90%</td><td></td></tr></table><ï½endâofâsentenceï½>",
        "provenance": {
          "page": 5
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 3,
      "tables_count": 0,
      "numerical_data_count": 58,
      "passages_count": 74,
      "entities_count": 20
    }
  }
}